$0.53
+0.14 (+34.12%)
Open$0.42
Previous Close$0.40
Day High$0.56
Day Low$0.42
52W High$7.29
52W Low$0.40
Volume—
Avg Volume5.00M
Market Cap49.42M
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Hold
16 analysts
Price Target
+2,126.0% upside
Current
$0.53
$0.53
Target
$11.82
$11.82
$9.31
$11.82 avg
$19.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 186.1K | 706.4K | 11.28M |
| Net Income | -74,182,554 | -253,374,947 | 2.04M |
| Profit Margin | -39,009.5% | -37,059.0% | 18.1% |
| EBITDA | -73,521,788 | -265,069,064 | 2.88M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | -73.7% | -73.7% | +22.8% |
| Debt/Equity | 0.01 | 0.01 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |